Advertisement

Cholesterol, Cholesterogenesis and Cancer

  • Marvin D. Siperstein
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 369)

Abstract

The suggestion that deranged cholesterol synthesis may play a role in carcinogenesis is not a new one. With characteristic prescience, Aldous Huxley anticipated the findings of the past few years linking cholesterol metabolism and cancer when he wrote as follows:

Some of the sterols were definitely poisonous… Longbottom had even suggested a connexion between fatty alcohols and neoplasms. In other words, cancer might be regarded, in the final analysis, as a symptom of sterol poisoning” (Huxley, 1939). Over the past few years, however, indeed in the past few months, there has been a remarkable burst of interest and publications suggesting not only that derangements in cholesterogenesis may relate to cancer, but that intervention in this synthetic pathway may specifically inhibit the growth of cancer cells.

Keywords

Feedback Control Cholesterol Synthesis Mevalonic Acid Sterol Synthesis FARNESYL Pyrophosphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bissell, D.M. and Alpert, E., 1972, The feedback control of hepatic cholesterol synthesis in Ugandan patients with liver disease. Cancer Res. 32:149–152.Google Scholar
  2. Bokoch, G.M. and Der, C.J., 1993 Emerging concepts in the Ras superfamily of GTP-binding proteins. FASEB J. 7:750–759.Google Scholar
  3. Bos, J.L., 1989, Ras oncogene in human cancer: A review. Cancer Res. 49:4682–4689.Google Scholar
  4. Bricker, L.A., Weis, H.S. and Siperstein, M.D., 1972, In vivo demonstration of the cholesterol feedback system by means of a desmosterol suppression technique. J. Clin. Invest. 51:197–205.CrossRefGoogle Scholar
  5. Chen, H.W., Heninger, H.J. and Kandutsch, A.A., 1975, Relationship between sterol synthesis and DNA synthesis in phytohemagglutinin-stimulated mouse lymphocytes. Proc. Natl. Acad. Sci. USA 72:1950–1954.CrossRefGoogle Scholar
  6. Elwood, J.C. and Morris, H.P., 1968, Lack of adaptation in lipogenesis by hepatoma 9121. J. Lipid Res. 9:337–341.Google Scholar
  7. Farnsworth, C.C., Wolda, S.L., Gelb, M.H. and Glomset, J.A., 1989, Human lamin contains a farnesylated cysteine residue. J. Biol. Chem. 264:20422–20429.Google Scholar
  8. Faust, J.R. and Dice, J.F., 1991, Evidence for isopentenyladenine modification on a cell cycle-regulated protein. J. Biol. Chem. 266:9961–9970.Google Scholar
  9. Feingold, K.R., Wiley, M.H., Moser, A.H. and Siperstein, M.D., 1983, Altered activation state of hydroxymethylglutaryl-coenzyme A reductase in liver tumors. Arch. Biochem. Biophys. 226:231–241.CrossRefGoogle Scholar
  10. Gould, R.G., 1951, Lipid metabolism and atherosclerosis. Am. J. Med. 11:209–227.CrossRefGoogle Scholar
  11. Hall, A., 1994, A biochemical function for Ras-At last. Science 264:1413–1414.CrossRefGoogle Scholar
  12. Hancock, J.F., Magee, A.I., Childs, J.E. and Marshall, C.J., 1989, All Ras proteins are polyisoprenylated but only some are polmitoylated. Cell 57:1167–1177.CrossRefGoogle Scholar
  13. Hara, M., Akasaka, K., Akinaga, S., Okabe, M., Nakano, H., Gomez, R., Wood, D., Uh, M. and Tamanoi, F., 1993, Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. USA 90:2281–2285.CrossRefGoogle Scholar
  14. Horton, B.J., Horton, J.D. and Sabine, J.R., 1972, Metabolic controls in precancerous liver. II. Loss of feedbackcontrol of cholesterol synthesis measured repeatedly in vivo during treatment with the carcinogens N-2-fluorenylacetamide and aflatoxin. Eur. J. Cancer 8:437–443.Google Scholar
  15. Horton, B.J., Horton, J.D. and Sabine, J.R., 1973, Metabolic controls in precancerous liver. V. Loss of control of cholesterol synthesis during feeding of the hepatocarcinogen 3′-methyl-4-dimethylaminoazobenzene. Eur. J. Cancer 9:573–576.Google Scholar
  16. Huneeus, V.Q., Wiley, M.H. and Siperstein, M.D., 1979, Essential role for mevalonate synthesis in DNA replication. Proc. Natl. Acad. Sci. USA 76:5056–5060.CrossRefGoogle Scholar
  17. Huxley, A. S, 1939, After Many A Summer Dies The Swan (Chapter 5), Harper and Brothers, New York/London.Google Scholar
  18. James, G.L., Goldstein, J.L., Brown, M.S., Rawson, T.E., Somers, T.C., McDowell, R.S., Crowley, C.W., Lucas, B.K., Levinson, A.D. and Marsters, Jr., J.C., 1993, Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells. Science 260:1937–1942.CrossRefGoogle Scholar
  19. Kandutsch, A.A. and Chen, H.W., 1977, Consequences of blocked sterol synthesis in cultured cells. J. Biol. Chem. 252:409–415.Google Scholar
  20. Kawata, S., Takaishi, K., Nagase, T., Ito, N., Matsuda, Y., Tamura, S., Matsuzawa, Y. and Tarui, S., 1990, Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res. 50:3270–3273.Google Scholar
  21. Kohl, N.E., Mosser, S.D., deSolms, S.J., Giuliani, E.A., Pompliano, D.L., Graham, S.L., Smith, R.L., Scolnick, E.M., Oliff, A. and Gibbs, J.B., 1993, Selective inhibition of Ras-dependent transformation by farnesyltransferase inhibitor. Science 260:1934–1937.CrossRefGoogle Scholar
  22. Lowry, D.R. and Willumsen, B.M., 1993, Function and regulation of RAS. Annu. Rev. Biochem. 62:851–891.CrossRefGoogle Scholar
  23. Miura, S., Hasumi, K. and Endo, A., 1993, Inhibition of protein prenylation by patulin. Fed. Euro. Biochem. Soc. 318:88–90.CrossRefGoogle Scholar
  24. Quesney-Huneeus, V., Hughes-Wiley, M. and Siperstein, M.D., 1980, Isopentenyladenine as a mediator of mevalonate-regulated DNa replication. Proc. Natl. Acad. Sci. USA 77:5842–5846.CrossRefGoogle Scholar
  25. Quesney-Huneeus, V., Galick, H.A. and Siperstein, M.D., 1983, The dual role of mevalonate in the cell cycle. J. Biol. Chem. 258:378–385.Google Scholar
  26. Sabine, J.R., Abraham, S. and Chaikoff, I.L., 1967, Control of lipid metabolism in hepatomas: insensitivity of rate of fatty acid and cholesterol synthesis by mouse hepatoma BW7756 to fasting and to feedback control. Cancer Res. 27:793–799.Google Scholar
  27. Schaber, M.D., O’Hara, M.B., Garsky, V.M., Mosser, S.D., Bergstrom, J.D., Moores, S.L., Marshall, M.S., Friedman, P.A., Dixon, R.A.F. and Gibbs, J.B., 1990, Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase. J. Biol. Chem. 265:14701–14704.Google Scholar
  28. Schafer, W.R., Trueblood, C.E., Yang, C.-C., Mayer, M.P., Rosenberg, S., Poulter, C.D., Kim, S.-H. and Rine, J., 1990, Enzymatic coupling of cholesterol intermediates to a mating pheromone precursor and to the Ras protein. Science 249:1133–1139.CrossRefGoogle Scholar
  29. Schafer, W.R. and Rine, J., 1992, Protein prenylation: Genes, enzymes, targets, and functions. Annu. Rev. Genet. 30:209–237.CrossRefGoogle Scholar
  30. Schmidt, R.A., Schneider, C.J. and Glomset, J.A., 1984, Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins. J. Biol. Chem. 259:10175–10180.Google Scholar
  31. Seabra, M.D., Reiss, Y., Casey, P.J., Brown, M.S. and Goldstein, J.L., 1991, Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. Cell 429-434.Google Scholar
  32. Silber, J.R., Galick, H., Wu, J.M. and Siperstein, M.D., 1992, The effect of mevalonic acid deprivation on enzymes of DNA replication in cells emerging from quiescence. Biochem. J. 288:883–889.Google Scholar
  33. Siperstein, M.D., 1966, Deletion of the cholesterol negative feedback system in precancerous liver. J. Clin. Invest. 45:1073.Google Scholar
  34. Siperstein, M.D., 1970, Regulation of cholesterol biosynthesis in normal and malignant tissues. Curr. Top. Cell. Regul. 2:65–100.Google Scholar
  35. Siperstein, M.D. and DoVale, H., Unpublished studies.Google Scholar
  36. Siperstein, M.D. and Fagan, V.M., 1964, Deletion of the cholesterol negative feedback system in liver tumors. Cancer Res. 24:1108–1115.Google Scholar
  37. Siperstein, M.D. and Fagan, V.M., 1966, Feedback control of mevalonate synthesis by dietary cholesterol. J. Biol. Chem. 241:602–609.Google Scholar
  38. Siperstein, M.D., Fagan, V.M. and Morris, H.P., 1966, Further studies on the deletion of the cholesterol feedback system in hepatomas. Cancer Res. 26:7–11.Google Scholar
  39. Siperstein, M.D. and Guest, M.J., 1966, Studies on the site of the feedback control of cholesterol synthesis. J. Clin. Invest. 39:642–652.CrossRefGoogle Scholar
  40. Siperstein, M.D., Gyde, A.M. and Morris, H.P., 1971, Loss of feedback control of hydroxymethylglutaryl coenzyme A reductase in hepatomas. Proc. Natl. Acad. Sci. USA 68:315–317.CrossRefGoogle Scholar
  41. Tomkins, G.M., Sheppard, H. and Chaikoff, I.L., 1953, Cholesterol synthesis by liver. III. Its regulation by ingested cholesterol. J. Biol. Chem. 201:137–141.Google Scholar
  42. Travis, J., 1993, Novel anticancer agents move closer to reality. Science 260:1877–1878.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Marvin D. Siperstein
    • 1
  1. 1.Department of Veterans Affairs Medical CenterUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations